摘要
目的寻找胃肠道间质瘤(GIST)患者格列卫耐药的标记物,指导格列卫的临床用药。方法采用免疫组织化学方法比较格列卫规范治疗后,耐药的患者耐药前后上皮膜蛋白-1(EMP-1)蛋白的表达水平。将GIST882细胞种植于裸鼠皮下形成移植瘤,裸鼠持续口服伊马替尼3周后传代,直至移植瘤耐药。比较耐药移植瘤与敏感移植瘤中EMP-1基因和蛋白表达水平的差异。结果伊马替尼耐药后,患者及移植瘤肿瘤组织中EMP-1表达较耐药前显著增加,伊马替尼耐药移植瘤中EMP-1的RNA水平较敏感移植瘤增加约11倍。结论EMP-1可以作为GIST耐药的标志物。
Objective To find a biomarker of imatinib-resistant gastrointestinal stromal tumors ( GIST), and further to explore a solution to Imatinib-resistance. Methods To Compare the expression of epithelial membrane protein-1 (EMP-1) between the Imatinib-sensitive GIST and the Imatinib-resistant GIST of the same patient by immunohistochemisty. A model of Imatinib-resistant nude mice xenograft was proposed by durative Imatinib treatment of the nude mice bearing subcutaneous GIST882 xenograft tumors. Then the expression of EMP-1 was compared in Imatinib-sensitive nude mice xenograft tumors and Imatinib-resistant xenograft tumors by immunohistochemisty and quantitative real-time polymerase chain reaction (qRT-PCR). Results EMP-1 was overexpressed in Imatinib-resistant GIST patient and nude mice xeno- graft tumors. The mRNA level in Imatinib-resistant nude mice xenograft tumors was 11-fold higher than that in Imatinib-sensitive nude mice xenograft tumor.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2012年第5期885-887,共3页
Chinese Journal of Experimental Surgery
基金
国家973计划资助项目(2009CB521802)
国家自然科学基金资助项目(30872472、30973496、30800569)
关键词
胃肠道间质瘤
复发
伊马替尼耐药
上皮膜蛋白-1
Gastrointestinal stromal tumors
Recurrence
Imatinib-resistance
Epithelial membrane protein-1